MedAssets valuation is exceptionally attractive, says RW Baird Baird believes the valuation of MedAssets is exceptionally attractive and raised its price target to $25 from $24. The firm cited recent contract wins, expansions, and believes it will hit its above Street Q4 guidance. Shares are Outperform rated.
News For MDAS From The Last 14 Days
Check below for free stories on MDAS the last two weeks.